JP2023526416A5 - - Google Patents

Info

Publication number
JP2023526416A5
JP2023526416A5 JP2022570441A JP2022570441A JP2023526416A5 JP 2023526416 A5 JP2023526416 A5 JP 2023526416A5 JP 2022570441 A JP2022570441 A JP 2022570441A JP 2022570441 A JP2022570441 A JP 2022570441A JP 2023526416 A5 JP2023526416 A5 JP 2023526416A5
Authority
JP
Japan
Prior art keywords
seq
tcr
cells
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033619 external-priority patent/WO2021237068A2/en
Publication of JP2023526416A publication Critical patent/JP2023526416A/ja
Publication of JP2023526416A5 publication Critical patent/JP2023526416A5/ja
Pending legal-status Critical Current

Links

JP2022570441A 2020-05-21 2021-05-21 Vgll1特異性を有するt細胞受容体およびその使用法 Pending JP2023526416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063028262P 2020-05-21 2020-05-21
US63/028,262 2020-05-21
PCT/US2021/033619 WO2021237068A2 (en) 2020-05-21 2021-05-21 T cell receptors with vgll1 specificity and uses thereof

Publications (2)

Publication Number Publication Date
JP2023526416A JP2023526416A (ja) 2023-06-21
JP2023526416A5 true JP2023526416A5 (cg-RX-API-DMAC7.html) 2024-05-23

Family

ID=76444666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570441A Pending JP2023526416A (ja) 2020-05-21 2021-05-21 Vgll1特異性を有するt細胞受容体およびその使用法

Country Status (8)

Country Link
US (1) US12552851B2 (cg-RX-API-DMAC7.html)
EP (1) EP4153301A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023526416A (cg-RX-API-DMAC7.html)
CN (1) CN115803084A (cg-RX-API-DMAC7.html)
AU (1) AU2021275239A1 (cg-RX-API-DMAC7.html)
CA (1) CA3178726A1 (cg-RX-API-DMAC7.html)
TW (1) TW202208418A (cg-RX-API-DMAC7.html)
WO (1) WO2021237068A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024163292A1 (en) * 2023-01-30 2024-08-08 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3964482A (en) 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えctla4ポリペプチドおよびその製造方法
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US8353861B2 (en) 2003-09-18 2013-01-15 Texmac, Inc. Applicator for applying functional substances into human skin
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1胜肽以及含此胜肽之疫苗
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3053932B1 (en) 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
WO2014036562A2 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
KR101714649B1 (ko) 2013-10-30 2017-03-10 한국생명공학연구원 암 치료 또는 암 전이 타겟으로서 vgll1의 용도
IL265834B2 (en) * 2016-10-07 2023-03-01 Univ Texas hla-restricted vgll1 peptides and their use

Similar Documents

Publication Publication Date Title
JP7755890B2 (ja) Car発現ベクター及びcar発現t細胞
US10561686B2 (en) Modified cell expansion and uses thereof
ES2692206T3 (es) Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades
TWI811278B (zh) 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞
JP2021521776A5 (cg-RX-API-DMAC7.html)
US11970545B2 (en) T cell-antigen coupler with Y182T mutation and methods of uses thereof
JP7591405B2 (ja) ユニバーサル抗原提示細胞およびその使用
US20180223255A1 (en) Activation and Expansion of T Cells
JP2018514204A (ja) ガンマデルタt細胞受容体(tcr)とキメラ抗原受容体(car)とを発現するt細胞
US11690874B2 (en) Use of chimeric antigen receptor modified cells to treat autoimmune disease
KR20200137030A (ko) 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
US11773384B2 (en) Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells
BR112021000735A2 (pt) acoplador de antígeno de células t com várias otimizações de construto
JP2022527813A (ja) Magea1特異的t細胞受容体およびその使用
CN112930394A (zh) 表达ii类主要组织相容性复合物的癌细胞疫苗和用于产生整合免疫应答的使用方法
TW202116797A (zh) Ii類mhc分子及其使用方法
JP2024519614A (ja) Prame特異的t細胞受容体とキメラ補助刺激受容体との組合せ
TW202118777A (zh) T細胞受體及其使用方法
JP2021525067A5 (cg-RX-API-DMAC7.html)
CN112585162B (zh) Ha-1特异性t细胞受体及其用途
Zhang et al. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer
TW202110462A (zh) T細胞受體及其使用方法
JP2023543556A (ja) Cd28膜貫通ドメインを有するキメラ抗原受容体(car)
US20240269182A1 (en) Modified Chimeric Antigen Receptor and Use thereof